Drugs / MSC-EVs
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06825572 | Apr 2025 → Mar 2026 overdue | liver failure | Third Affiliated Hospital, Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05940610 | Sep 2023 → Sep 2024 | acute liver failure | Third Affiliated Hospital, Sun Yat-Sen University | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSC-EVs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05940610 ↗ |
| Known as | MSC-EV | “Patients participated in the experimental cohort will be infused with a single dose of 10 E10 MSC-EV particles per 100ml” NCT05940610 ↗1“mesenchymal stem cells-derived extracellular vesicles (MSC-EV)” NCT06825572 ↗ |
| Modality | Other / unclassified | “mesenchymal stem cells-derived extracellular vesicles (MSC-EVs)” NCT05940610 ↗ |
| Route | Other | “an additional injection of MSC-EVs will be received by participants once a week for 4 weeks” NCT05940610 ↗ |